Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:39 PM ET 8-K
Capital Raise SmartStop Self Storage REIT, Inc. SMA

SmartStop Self Storage REIT Capital Raise of $334M

SmartStop Self Storage REIT entered into forward sale agreements for an aggregate of 9,372,500 shares of common stock at an initial forward price of $35.6125 per share. The offering includes 8,150,000 initial shares and 1,222,500 shares from the full exercise of the underwriters' overallotment option. The company intends to use the net proceeds from the eventual settlement of these agreements to fund pending investments, including a Canadian joint venture and potential acquisitions.

Value
$334M
Term
through Sept 2028
4:39 PM ET Form 4
Insider Selling United Therapeutics Corp UTHR

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.64M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $584.20 to $598.63 a share (average $593.99) in 14 transactions, worth $5.64M in total on Nov 11, 2026. Shares held after the trade: 324,443 (-0.1%).

Value
$5.64M
Shares
9,500
Average price
$593.99
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Nov 11, 2026
4:39 PM ET Form 4
Insider Selling Amkor Technology, Inc. AMKR

Amkor Technology CFO Megan Faust Sells $35K of Stock

Megan Faust, CFO, sold 1,000 shares of Amkor Technology, Inc. at $35.00 a share, worth $35K in total on Nov 10, 2026. Shares held after the trade: 132,105 (-0.8%).

Value
$35K
Shares
1,000
Price
$35.00
Role
CFO
Holding change
-0.8%
Trade date
Nov 10, 2026
4:38 PM ET 10-Q
Financial Results Gaxos.Ai Inc. GXAI

Gaxos.Ai Q3 2026 Results: Net Loss of $930K, Loss Narrows

GAXOS.AI INC. reported a significant revenue increase to $7.08 million for the nine months ended September 30, 2026, compared to $0.69 million in the prior year, driven by a $1.75 million gain on the sale of gaming assets. Despite the revenue growth, the company incurred a net loss attributable to common shareholders of $2.86 million due to a substantial rise in selling, general, and administrative expenses.

Key figure
Net loss $930K
4:38 PM ET Form 4
Insider Selling Magnite, Inc. MGNI

Magnite CTO David Buonasera Sells $25.3K of Stock

David Buonasera, CTO, sold 871 shares of Magnite, Inc. at $29.00 a share, worth $25.3K in total on Nov 9, 2026. Shares held after the trade: 238,578 (-0.4%).

Value
$25.3K
Shares
871
Price
$29.00
Role
CTO
Holding change
-0.4%
Trade date
Nov 9, 2026
4:38 PM ET Form 4
Insider Selling United Therapeutics Corp UTHR

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.57M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $577.52 to $592.93 a share (average $586.32) in 14 transactions, worth $5.57M in total on Nov 10, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.57M
Shares
9,500
Average price
$586.32
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Nov 10, 2026
4:38 PM ET 10-Q
Financial Results Liquidmetal Technologies Inc LQMT

Liquidmetal Technologies Q3 2026 Results: Net Loss of $767K, Loss Widens

Liquidmetal Technologies reported a net loss of $2.37 million for the nine months ended September 30, 2026, compared to $1.64 million in the prior year period. While product revenue increased slightly to $674 thousand, the company faced higher operating expenses and a $220 thousand loss on the disposal of property and equipment.

Key figure
Net loss $767K
4:38 PM ET 10-Q
Financial Results American National Group Inc. ANG-PD

American National Group Q3 2026 Results: Net Income $945M, Up 331.5% YoY

American National Group Inc. reported net income attributable to common stockholders of $939 million for the third quarter of 2026, a significant increase from $208 million in the prior year period. Total assets remained stable at $130.5 billion, while total equity decreased to $8.1 billion primarily due to a $2.2 billion unrealized investment loss recorded in other comprehensive income.

Key figure
Net income $945M · +331.5% YoY
4:38 PM ET 10-Q
Financial Results Commonwealth Credit Partners BDC I, Inc.

Commonwealth Credit Partners BDC I Q3 2026 Results: Net Income $4.9M, Down 27.3% YoY

For the nine months ended September 30, 2026, Commonwealth Credit Partners BDC I, Inc. reported total investment income of $45.8 million and net investment income of $35.5 million, both down from the prior year period. Net asset value per share decreased to $866.13 from $895.75 at year-end 2025, primarily driven by $17.2 million in net unrealized losses on investments.

Key figure
Net income $4.9M · -27.3% YoY
4:37 PM ET Form 4
Insider Selling Magnite, Inc. MGNI

Magnite CFO Brian Gephart Sells $106K of Stock

Brian Gephart, CFO, sold 3,700 shares of Magnite, Inc. at $28.78 a share, worth $106K in total on Nov 9, 2026. Shares held after the trade: 163,310 (-2.2%).

Value
$106K
Shares
3,700
Price
$28.78
Role
CFO
Holding change
-2.2%
Trade date
Nov 9, 2026
4:37 PM ET 8-K
M&A Deal Advanced Drainage Systems, Inc. WMS

Advanced Drainage Systems M&A Deal with StormTrap Investments LLC

Advanced Drainage Systems, Inc. (ADS) has completed its acquisition of StormTrap Investments LLC from PSP Capital. The deal expands ADS's addressable market in highly engineered stormwater storage solutions and provides cross-selling opportunities within the water management industry.

Counterparty
StormTrap Investments LLC
4:37 PM ET 10-Q
Financial Results Bain Capital Private Credit

Bain Capital Private Credit Q3 2026 Results: Net Income $32.4M, Up 51.8% YoY

Bain Capital Private Credit reported total investment income of $173.3 million for the nine months ended September 30, 2026, a significant increase from $88.3 million in the prior year period. Net investment income grew to $83.1 million as the company expanded its investment portfolio to $2.4 billion at fair value, up from $1.68 billion at the end of 2025.

Key figure
Net income $32.4M · +51.8% YoY
4:36 PM ET 10-Q
Financial Results AIM ImmunoTech Inc. AIM

AIM ImmunoTech Q3 2026 Results: Net Loss of $3.14M, Loss Narrows

AIM ImmunoTech reported a net loss of $9.95 million for the nine months ended September 30, 2026, compared to $9.78 million in the prior year. The company significantly strengthened its balance sheet through equity offerings and warrant exercises, increasing total assets to $9.75 million and achieving a positive stockholders' equity of $7.08 million.

Key figure
Net loss $3.14M
4:36 PM ET 10-Q
Financial Results SES AI Corp SES

SES AI Q3 2026 Results: Net Loss of $13.4M, Loss Narrows

SES AI Corp reported total current assets of $161.6 million as of September 30, 2026, a decrease from $216.3 million at year-end 2025, primarily driven by a reduction in short-term investments. The company continues to incur losses and highlights risks related to its drone cell manufacturing, AI-based services, and the integration of UZ Energy.

Key figure
Net loss $13.4M
4:36 PM ET Form 4
Insider Buying Industrial Logistics Properties Trust ILPT

Industrial Logistics Properties Trust Insider Kevin C. Phelan Buys $12K of Stock

Kevin C. Phelan bought 2,000 shares of Industrial Logistics Properties Trust at $6.01 a share, worth $12K in total on Nov 9, 2026. Shares held after the trade: 9,500 (+26.7%).

Value
$12K
Shares
2,000
Price
$6.01
Holding change
+26.7%
Trade date
Nov 9, 2026
4:36 PM ET 10-Q
Financial Results Journey Medical Corp DERM

Journey Medical Q3 2026 Results: Net Loss of $1.31M, Loss Narrows

Journey Medical Corp reported a 16.7% increase in total revenue to $53.4 million for the nine months ended September 30, 2026, compared to the prior year. The company significantly reduced its net loss from $10.2 million to $3.9 million over the same period, driven by improved operating margins and lower research and development expenses.

Key figure
Net loss $1.31M
4:36 PM ET 8-K
Leadership Change Target Corp TGT

Target Leadership Change

Target Corporation has elected Sally Grimes to its Board of Directors, effective December 1, 2026. Ms. Grimes, the former CEO of Diageo North America and Clif Bar & Company, will serve on the Audit & Risk and Infrastructure & Finance committees. Her appointment is intended to bring extensive consumer brand and innovation expertise to Target's long-term growth strategy.

4:36 PM ET 8-K
Leadership Change Xerox Holdings Corp XRX

Xerox Holdings Leadership Change

William Twomey, Vice President and Chief Accounting Officer, has resigned from Xerox Holdings Corporation effective November 30, 2026, to pursue other opportunities. Chuck Butler, the company's current CFO, will serve as the interim principal accounting officer while a search for a permanent replacement is conducted.

4:36 PM ET 10-Q
Financial Results Pono Capital Four, Inc. PONO

Pono Capital Four Q3 2026 Results: Net Income $507K

Pono Capital Four, Inc. reported a net income of $1,571,816 for the period from inception (January 2, 2026) through September 30, 2026, primarily driven by $2,346,853 in income earned on marketable securities held in the Trust Account. As a shell company, it maintains $122,346,853 in its Trust Account while reporting a shareholders' deficit of $2,654,584 due to the redemption value of Class A ordinary shares.

Key figure
Net income $507K
4:36 PM ET 8-K
Financial Results Gemini Space Station, Inc. GEMI

Gemini Space Station Financial Results

Gemini Space Station reported Q3 2026 total revenue of $40.9 million, a 19% year-over-year decline driven by a 73% drop in platform spot trading volume. Despite the revenue decline, the company improved its net loss by 63% year-over-year to $58.6 million through a 30% reduction in operating expenses and lower headcount.

Term
Q3 2026

“Operating expenses declined for a third consecutive quarter, and as we invest in growth, we intend to stay disciplined about where those dollars go. We’re clear-eyed about the work ahead and committed to getting it right: deepening our relationships with the customers who use Gemini, continuing to iterate, and investing where customers and markets are headed. We expect to be judged on results, and we intend to earn the confidence of our customers and shareholders one quarter at a time.”

Tyler Winklevoss, CEO of Gemini

“We started Gemini in 2014 because we believed crypto would change how people save, spend and move value, and we’re in this for the long term. Gemini 2.0 is our bet that the platforms that last will be the ones that own the regulated infrastructure underneath. We’re building ours to serve customers directly and to be something other platforms can build on.”

Cameron Winklevoss, President of Gemini
4:36 PM ET 8-K
Licensing Deal Tempest Therapeutics, Inc. TPST

Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.

Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.

Counterparty
Hebei Senlang Biotechnology Co., Ltd.

“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”

Matt Angel, Ph.D., President and Chief Executive Officer of Tempest

“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”

Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
4:36 PM ET Form 4
Insider Selling Core Scientific, Inc. CORZ

Core Scientific Insider Todd M. Duchene Sells $125K of Stock

Todd M. Duchene sold 10,000 shares of Core Scientific, Inc. at $12.39 to $12.70 a share (average $12.45) in 2 transactions, worth $125K in total on Nov 9, 2026. Shares held after the trade: 1,113,286 (-0.2%).

Value
$125K
Shares
10,000
Average price
$12.45
Holding change
-0.2%
Trade date
Nov 9, 2026
4:36 PM ET 10-Q
Financial Results enCore Energy Corp. EU

enCore Energy Q3 2026 Results: Net Loss of $33.9M, Loss Widens

enCore Energy Corp. is a non-accelerated filer and smaller reporting company focused on uranium exploration and extraction. As of November 9, 2026, the company had 195,668,102 common shares outstanding and reported a history of negative operating cash flows while pursuing an expansion-by-acquisition strategy.

Key figure
Net loss $33.9M
4:36 PM ET Form 4
Insider Selling Datadog, Inc. DDOG

Datadog CTO Alexis Le-Quoc Sells $8.97M of Stock

Alexis Le-Quoc, CTO, sold 49,961 shares of Datadog, Inc. at $178.01 to $181.68 a share (average $179.52) in 5 transactions, worth $8.97M in total on Nov 9, 2026. Shares held after the trade: 438,072 (-0.0%).

Value
$8.97M
Shares
49,961
Average price
$179.52
Role
CTO
Holding change
-0.0%
Trade date
Nov 9, 2026
4:36 PM ET 10-Q
Financial Results Cibus, Inc. CBUS

Cibus Q3 2026 Results: Net Loss of $21.9M, Loss Narrows

Cibus, Inc. reported a net loss of $21.9 million for the third quarter of 2026, with revenue increasing to $0.8 million from $0.6 million in the prior year period. The company's cash position improved slightly to $10.7 million as of September 30, 2026, supported by $31.0 million in net cash provided by financing activities during the first nine months of the year.

Key figure
Net loss $21.9M
4:36 PM ET 8-K
Loan & Debt Nakamoto Inc. NAKA

Nakamoto $165M Debt Financing with Kraken

Nakamoto Inc. entered into a second amendment to its Master Loan Agreement with Kraken to extend the maturity of 60 million USDT of its 165 million USDT outstanding principal from December 2026 to December 2027. The amendment also allows the company to include the net value of its Bitcoin derivatives positions as collateral, providing greater flexibility to manage Bitcoin price volatility. Following the update, the company has no scheduled principal payments due until June 2027.

Value
$165M
Counterparty
Kraken
Term
through Dec 2027
4:35 PM ET 10-Q
Financial Results Spero Therapeutics, Inc. SPRO

Spero Therapeutics Q3 2026 Results: Net Loss of $44.3M, Loss Widens

Spero Therapeutics reported that the FDA approved GSK’s NDA resubmission for Utebzi in June 2026, shifting the company's focus to the development of SP001. As of November 6, 2026, the company had 58,264,577 shares of common stock outstanding and continues to rely on milestone payments and royalties from its GSK partnership to fund operations.

Key figure
Net loss $44.3M
4:35 PM ET Form 4
Insider Selling Magnite, Inc. MGNI

Magnite Insider Katie Seitz Evans Sells $758K of Stock

Katie Seitz Evans sold 26,178 shares of Magnite, Inc. at $28.96 a share, worth $758K in total on Nov 9, 2026. Shares held after the trade: 415,622 (-5.9%).

Value
$758K
Shares
26,178
Price
$28.96
Holding change
-5.9%
Trade date
Nov 9, 2026
4:35 PM ET 8-K
Financial Results CapsoVision, Inc CV

CapsoVision Financial Results

CapsoVision reported Q3 2026 revenue of $3.6 million and a gross margin of 49%, while highlighting the recent FDA clearance and launch of its AI Highlights tool. The company also completed enrollment for its second-generation CapsoCam Colon study and raised approximately $19.5 million in net proceeds through a registered direct offering and ATM program during the quarter.

Term
Q3 2026

“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision. Our four-camera, 360-degree panoramic capsule already provides physicians with a differentiated view of the small bowel. By combining that imaging capability with AI-assisted review, we believe we can reduce reading time, improve detection accuracy compared with manual review, and give physicians an additional level of diagnostic confidence.”

Johnny Wang, President and Chief Executive Officer

“At the same time, completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity. With the support of our existing shareholders through our recent financing, we are focused on translating these milestones into broader adoption and long-term growth.”

Johnny Wang, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.